Q2 2026 · Form 13F Ledger数据来源:SEC EDGAR  
H

HOLDER.TOP

谁持有什么——美股机构持仓的季度账本。
EN · 简 · 繁
机构 / Cormorant Asset Management, LP
Form 13F · Q2 2026

Cormorant Asset Management, LP

CIK 1583977申报日 2026-08-1413F-HR 在 EDGAR 查看原始申报 ↗
$19.5亿
申报组合市值
50
持仓数量
12
Quarters on record
Top 50
持仓数量

Cormorant Asset Management, LP——持仓

共 50 个持仓中的前 50 名,按申报市值排名。股数变动与上一季度对比。
#证券股数股数环比市值占其组合
1PRAX Praxis Precision Medicines I640,000−27.7%$2.1亿11.0%
2BBOT Bridgebio Oncology Therapeut17.9M+0.0%$1.4亿7.0%
3PBLS Parabilis Medicines Inc4.6M—$1.3亿6.5%
4RAPP Rapport Therapeutics Inc2.7M−10.1%$1.1亿5.7%
5ERAS Erasca Inc6.0M+3.4%$1.1亿5.6%
6EWTX Edgewise Therapeutics Inc2.5M−23.0%$1.0亿5.2%
7EYPT Eyepoint Inc7.0M−15.3%$1.0亿5.1%
8ALMS Alumis Inc3.3M−16.8%$9246万4.7%
9ABVX Abivax Sa675,000−11.2%$8995万4.6%
10DNTH Dianthus Therapeutics Inc750,000−21.1%$7311万3.7%
11DRUG Bright Minds Biosciences Inc900,000−15.0%$6318万3.2%
12MLTX Moonlake Immunotherapeutics3.2M−28.5%$6241万3.2%
13BIOA Bioage Labs Inc2.4M−17.3%$5859万3.0%
14ORKA Oruka Therapeutics Inc533,340+0.0%$5076万2.6%
15ANL Adlai Nortye Ltd4.0M+37.3%$4575万2.3%
16BBIO Bridgebio Pharma Inc550,000−35.3%$4096万2.1%
17TNGX Tango Therapeutics Inc1.3M−8.8%$4064万2.1%
18BHVN Biohaven Ltd2.6M+48.3%$3884万2.0%
19AGMB Agomab Therapeutics Nv2.5M+0.0%$3200万1.6%
20MBX Mbx Biosciences Inc550,000−50.9%$3036万1.6%
21CLYM Climb Bio Inc2.1M—$2746万1.4%
22OLEMA PHARMACEUTICALS INC Olema Pharmaceuticals Inc2.1M−44.9%$2690万1.4%
23DMRA Damora Therapeutics Inc1.0M−34.4%$2601万1.3%
24PHVS Pharvaris N V750,000−25.0%$2594万1.3%
25CRBP Corbus Pharmaceuticals Hldgs2.3M+0.0%$2200万1.1%
26SYRE Spyre Therapeutics Inc225,000—$1998万1.0%
27DFTX Definium Therapeutics Inc400,000—$1882万1.0%
28NAMS Newamsterdam Pharma Company500,000−47.4%$1694万0.9%
29ROIV Roivant Sciences Ltd475,000−36.7%$1681万0.9%
30CABA Cabaletta Bio Inc5.0M−9.1%$1555万0.8%
31HLXC Helix Acquisition Corp Iii1.3M+0.0%$1381万0.7%
32ASND Ascendis Pharma A/S50,000—$1334万0.7%
33KLRA Kailera Therapeutics Inc550,000—$1212万0.6%
34INSM Insmed Inc75,000−60.5%$800万0.4%
35FTH Faeth Therapeutics Inc1.0M+235.8%$766万0.4%
36ELVN Enliven Therapeutics Inc150,000—$761万0.4%
37TARS Tarsus Pharmaceuticals Inc100,000−55.6%$629万0.3%
38IBIO Ibio Inc3.6M—$625万0.3%
39CRINETICS PHARMACEUTICALS IN Crinetics Pharmaceuticals In125,000−50.0%$468万0.2%
40ARQT Arcutis Biotherapeutics Inc175,000−61.1%$459万0.2%
41ARWR Arrowhead Pharmaceuticals In50,000−50.0%$408万0.2%
42GPCR Structure Therapeutics Inc75,000−57.1%$403万0.2%
43RACC Research Alliance Corp Iii370,000—$396万0.2%
44COGT Cogent Biosciences Inc100,000−50.0%$387万0.2%
45ALT Altimmune Inc1.2M—$380万0.2%
46AMLX Amylyx Pharmaceuticals Inc200,000−42.9%$359万0.2%
47ODTX Odyssey Therapeutics Inc175,000—$327万0.2%
48PCVX Vaxcyte Inc50,000−50.0%$291万0.1%
49BOLD Boundless Bio Inc1.0M—$250万0.1%
50QUINCE THERAPEUTICS INC Quince Therapeutics Inc5,498—$10万0.0%
来源:经 SEC EDGAR 的 Form 13F 申报。持仓截至 2026 年 6 月 30 日。期权(看涨/看跌)不计入股数。